WebDoctor Encyclopedia

Article

HIPEC and Cytoreductive Surgery

What are cytoreductive surgery and HIPEC?

Cytoreductive surgery (CRS) is a major operation to remove all visible cancer from the peritoneum, the thin lining of the abdomen, and from the organs it covers. HIPEC stands for hyperthermic intraperitoneal chemotherapy. It means bathing the inside of the abdomen with heated chemotherapy for a set time during the same operation, once the visible tumour has been removed.

The two are usually combined and often described together as CRS and HIPEC, or sometimes informally as the “Sugarbaker procedure”, after the surgeon who helped develop it. The aim is to remove every visible tumour deposit with surgery, and then use the heated chemotherapy to reach tiny cancer cells that cannot be seen.

CRS and HIPEC is a long and demanding operation offered only at specialist peritoneal centres. For carefully chosen people with cancer that has spread within the abdomen but nowhere else, it can give long-term control and, for some cancers, a chance of cure.

1. Key facts at a glance

Feature Details
Type of treatment Major surgery combined with heated chemotherapy inside the abdomen
Main uses Pseudomyxoma peritonei, peritoneal mesothelioma, selected colorectal and ovarian cancers with peritoneal spread
Anaesthetic General anaesthetic, usually with an epidural
Length of operation Often 6-12 hours
HIPEC time Usually 30-90 minutes, depending on the drug
Hospital stay About 1-3 weeks, often including a short stay in intensive care
Recovery Usually 2-3 months before feeling close to normal
Main risks Bleeding, infection, bowel leaks, blood clots, prolonged recovery

2. How it works

Why the peritoneum is a special case

Some cancers spread by shedding cells into the abdominal cavity, where they settle on the peritoneal surfaces. Chemotherapy given into a vein reaches these surface deposits poorly, because the peritoneum has a limited blood supply. Placing chemotherapy directly into the abdomen allows much higher drug levels to reach the cancer cells while less drug enters the bloodstream.

The role of each part

Component What it does
Peritonectomy Stripping away diseased areas of the abdominal lining
Organ removal Removing affected organs or parts of them, such as the omentum, spleen, gallbladder, part of the bowel, ovaries or womb
Heat Warming the chemotherapy to about 41-43 C makes cancer cells more sensitive and helps the drug penetrate tissue
Intraperitoneal chemotherapy Delivers high drug levels to the surfaces where microscopic cancer may remain

The Peritoneal Cancer Index

Surgeons score how much cancer is present using the Peritoneal Cancer Index (PCI). The abdomen is divided into 13 regions, and each is scored from 0 to 3 according to the size of the largest deposit, giving a total from 0 to 39. A lower score generally means a better chance of complete removal and a better outcome. A review of the principles of treatment emphasised that results are best when CRS and HIPEC are performed at a low PCI and when complete cytoreduction is achieved (Sugarbaker, 2015).

3. Who it is for

Conditions treated

Condition Role of CRS and HIPEC
Pseudomyxoma peritonei Standard treatment when the disease can be removed
Appendiceal neoplasms Mucinous and other appendix tumours that have spread to the peritoneum
Peritoneal mesothelioma Main treatment for suitable people with disease limited to the abdomen
Colorectal adenocarcinoma Complete cytoreduction is key; the added value of HIPEC is debated
Epithelial ovarian cancer HIPEC during interval surgery after chemotherapy in selected women
High-grade serous ovarian carcinoma As above, in specialist settings
Gastric adenocarcinoma Limited peritoneal spread in selected people, often within trials
Desmoplastic small round cell tumour Sometimes used in specialist centres alongside chemotherapy and radiotherapy

Who may be suitable

Factor Typical requirement
Spread Cancer limited to the abdomen, with no distant spread such as to the lungs
Amount of disease Low enough that all visible tumour can be removed
Fitness Good general health to withstand a long operation
Response to chemotherapy For some cancers, the disease should be stable or responding
Nutrition Adequate nutritional state, or improved before surgery

Who is usually not suitable

Situation Reason
Spread outside the abdomen Surgery cannot remove all cancer
Very extensive disease involving the small bowel Complete removal may be impossible without losing too much bowel
Poor fitness or major heart or lung disease High risk from the operation
Rapidly growing cancer on chemotherapy Benefit is unlikely

4. Before treatment

Step Why it is done
CT, MRI and sometimes PET scans Estimate the extent of disease
Tumour markers CEA, CA125, CA19-9 or others, depending on the cancer
Diagnostic laparoscopy Keyhole look inside the abdomen to measure disease before committing to a large operation
Fitness testing Heart and lung tests, sometimes a cardiopulmonary exercise test
Prehabilitation Exercise, nutrition and stopping smoking to prepare for surgery
Stoma counselling If part of the bowel may need to be brought out as a stoma
Multidisciplinary review Surgeons, oncologists and radiologists agree the plan

5. What to expect: step by step

Step What happens
1. Anaesthetic General anaesthetic and usually an epidural for pain relief
2. Opening the abdomen A long midline incision is made from below the breastbone to the pubic bone
3. Assessment The surgeon scores the PCI and decides if complete cytoreduction is possible
4. Cytoreduction Tumour deposits, affected lining and organs are removed; this can take many hours
5. HIPEC Tubes are placed and heated chemotherapy is circulated through the abdomen by a pump, for about 30-90 minutes
6. Draining and washing The chemotherapy is drained and the abdomen is rinsed
7. Reconnection Bowel ends are joined, or a stoma is formed
8. Closure The abdomen is closed, often with drains in place
9. Intensive care or high-dependency unit Close monitoring for the first one to several days
10. Ward recovery Gradual return to eating, walking and independence

Open and closed techniques

In the open method, the abdomen is kept open and the surgeon gently moves the fluid by hand so it reaches every surface. In the closed method, the abdomen is temporarily closed while the fluid circulates. Both are used, and centres choose based on experience.

Drugs commonly used

Drug Typical setting
Mitomycin C Pseudomyxoma peritonei, appendix and colorectal cancer
Cisplatin Ovarian cancer and mesothelioma, sometimes with doxorubicin
Oxaliplatin Colorectal cancer in some centres, though its use has fallen

6. Side effects and risks

CRS and HIPEC is one of the largest operations in cancer surgery, and complications are common.

Risk Notes
Pain Managed with an epidural and other pain relief
Slow return of bowel function Feeding through a vein or tube may be needed for a time
Anastomotic leak or bowel perforation A leak where the bowel was joined; may need further surgery
Infection Wound, chest or abdominal infection
Bleeding May need transfusion or return to theatre
Blood clots Prevented with injections and stockings
Low blood counts From absorbed chemotherapy
Kidney problems Particularly with cisplatin
Fluid collections May need drainage
Stoma Temporary or permanent in some people
Death A small risk at experienced centres

Evidence on complications

In the PRODIGE 7 trial, serious complications at 30 days were similar with and without oxaliplatin HIPEC, but by 60 days they were more frequent in the HIPEC group (Quenet et al., 2021).

7. Results and outlook

Study Main finding
OVHIPEC-1, stage III ovarian cancer (245 women) Adding cisplatin HIPEC to interval surgery after chemotherapy lengthened median survival from 33.9 to 45.7 months, with similar rates of severe side effects (van Driel et al., 2018)
PRODIGE 7, colorectal peritoneal metastases (265 people) After complete cytoreduction, adding 30 minutes of oxaliplatin HIPEC did not improve survival; median survival was about 41 months in both groups (Quenet et al., 2021)
Pseudomyxoma peritonei consensus Expert societies strongly recommend CRS and HIPEC over simple debulking; observational studies report around 80% of people alive at five years (Kusamura et al., 2025)

Making sense of PRODIGE 7

PRODIGE 7 showed that people with colorectal peritoneal metastases who had complete cytoreduction lived much longer than older figures would suggest, but it could not show that the short oxaliplatin HIPEC itself added benefit. As a result, many centres now focus on complete surgery for colorectal cancer, and some use different drugs or longer HIPEC within trials. The completeness of cytoreduction remains the single most important factor across all cancers.

8. Recovery and aftercare

Recovery timeline

Period What to expect
Days 1-3 Intensive or high-dependency care; drains and tubes in place
Days 3-10 Gradual return to drinking and eating; walking with help
Weeks 1-3 Discharge home when eating and moving well
Weeks 3-12 Tiredness, reduced appetite and weight loss slowly improve
Months 3-6 Many people return to work or normal activities

Practical tips

  • Walk a little more each day to rebuild strength and reduce clot risk
  • Eat small, frequent meals; a dietitian can help if weight loss continues
  • Avoid heavy lifting for at least 6-8 weeks to protect the wound
  • Learn stoma care before leaving hospital if you have one
  • Report fever, worsening pain, vomiting or wound redness to your team

Further treatment

Depending on the cancer, more chemotherapy may be given after recovery. For ovarian cancer, this is a standard part of the plan. For pseudomyxoma peritonei and mesothelioma, follow-up with scans and tumour markers may be all that is needed.

Follow-up

Check Typical timing
Clinic review Every 3-6 months at first
Tumour markers At each visit
CT or MRI scans Every 6-12 months, more often at first
Long-term follow-up Often for 10 years or more for pseudomyxoma peritonei

Emotional recovery

Recovering from such a large operation can be slow and frustrating, and many people feel low or anxious in the first months. Specialist peritoneal centres usually have nurse specialists and support groups. Talking with others who have been through CRS and HIPEC can help set realistic expectations.

9. Alternatives

Alternative When it is considered
Systemic chemotherapy alone When surgery cannot remove all disease, or as the main treatment for many cancers
Debulking surgery without HIPEC To relieve symptoms when complete removal is not possible
PIPAC (pressurised intraperitoneal aerosol chemotherapy) Keyhole delivery of chemotherapy spray for people unsuitable for CRS, mainly in trials
Immunotherapy or targeted therapy Depending on the cancer’s features; see immune checkpoint inhibitors
Clinical trials Different HIPEC drugs or techniques
Supportive and palliative care Symptom control, including drainage of fluid

10. Frequently asked questions

Question Answer
Is HIPEC the same as normal chemotherapy? No; it is a single treatment given into the abdomen during surgery
Will I lose my hair? Usually not from HIPEC alone
Will I need a stoma? Sometimes, depending on which parts of the bowel are removed
How long is the operation? Often 6-12 hours, sometimes longer
Why is it only done at certain hospitals? Results are better at centres with large experience
Can it be repeated? Sometimes, for recurrence of slow-growing disease such as pseudomyxoma
Will I be cured? It depends on the cancer; cure is possible for some, especially pseudomyxoma and mesothelioma

11. Questions to ask your care team

  • What is my Peritoneal Cancer Index, and can all disease be removed?
  • What are my chances of a complete cytoreduction?
  • Which organs may need to be removed?
  • Which drug will be used for HIPEC, and why?
  • How many of these operations does your centre perform each year?
  • What complications are most likely for me?
  • Will I need chemotherapy before or after surgery?

Resources

  1. Kusamura, S. et al. (2025) ‘Multisocietal consensus on the use of cytoreductive surgery and HIPEC for the treatment of pseudomyxoma peritonei: a GRADE approach for evidence evaluation and recommendation’, Journal of Surgical Oncology, 132(5), pp. 810-816.
  2. Quenet, F. et al. (2021) ‘Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial’, The Lancet Oncology, 22(2), pp. 256-266.
  3. Sugarbaker, P.H. (2015) ‘Management of peritoneal metastases – basic concepts’, Journal of BUON, 20(Suppl 1), pp. S2-S11.
  4. van Driel, W.J. et al. (2018) ‘Hyperthermic intraperitoneal chemotherapy in ovarian cancer’, New England Journal of Medicine, 378(3), pp. 230-240.
  5. National Cancer Institute (2026) Colon Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq (Accessed: October 2026).
  6. National Cancer Institute (2026) Ovarian Epithelial, Fallopian, and Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.